Cullen Capital Management LLC Buys New Position in Varex Imaging $VREX

Cullen Capital Management LLC acquired a new position in shares of Varex Imaging (NASDAQ:VREX) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 28,808 shares of the company’s stock, valued at approximately $300,000. Cullen Capital Management LLC owned 0.07% of Varex Imaging as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in VREX. Algert Global LLC grew its stake in shares of Varex Imaging by 22.5% in the 2nd quarter. Algert Global LLC now owns 264,088 shares of the company’s stock valued at $2,754,000 after buying an additional 48,453 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Varex Imaging during the 2nd quarter worth approximately $3,061,000. Globeflex Capital L P bought a new position in Varex Imaging in the second quarter worth approximately $826,000. EP Wealth Advisors LLC bought a new position in Varex Imaging in the second quarter worth approximately $207,000. Finally, Ieq Capital LLC acquired a new stake in Varex Imaging in the second quarter valued at approximately $325,000.

Varex Imaging Stock Performance

Shares of Varex Imaging stock opened at $18.50 on Wednesday. The company has a market cap of $778.85 million, a PE ratio of 35.58 and a beta of 0.89. Varex Imaging has a 52 week low of $9.09 and a 52 week high of $18.63. The business has a 50 day moving average price of $12.70 and a 200-day moving average price of $11.89. The company has a quick ratio of 1.53, a current ratio of 3.38 and a debt-to-equity ratio of 0.64.

Varex Imaging (NASDAQ:VREX) last announced its earnings results on Monday, August 10th. The company reported $0.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.10. Varex Imaging had a return on equity of 9.19% and a net margin of 2.55%.The company had revenue of $210.50 million for the quarter, compared to analysts’ expectations of $215.50 million. Equities analysts anticipate that Varex Imaging will post 0.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently commented on VREX. Sidoti restated a “neutral” rating and set a $19.00 price objective on shares of Varex Imaging in a report on Monday, August 10th. Zacks Research cut Varex Imaging from a “strong-buy” rating to a “hold” rating in a report on Monday, July 27th. B. Riley Financial downgraded shares of Varex Imaging from a “buy” rating to a “hold” rating in a research report on Monday, August 10th. CJS Securities lowered shares of Varex Imaging from an “outperform” rating to a “market perform” rating in a research note on Monday, August 17th. Finally, Weiss Ratings upgraded shares of Varex Imaging from a “sell (d-)” rating to a “sell (d+)” rating in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $16.88.

About Varex Imaging

Varex Imaging Corporation is a global provider of X-ray imaging components and solutions for the medical, security and industrial markets. The company designs, develops and manufactures a broad range of products that convert X-ray energy into high-resolution digital images. Its portfolio includes X-ray tubes, flat panel detectors, digital sensors, specialty radiographic tubes and related software, all engineered to meet the demanding requirements of original equipment manufacturers (OEMs) in diagnostic imaging, computed tomography (CT), fluoroscopy, mammography, dental radiography and non-destructive testing applications.

The company’s medical imaging offerings support a wide spectrum of clinical modalities, from portable radiography systems to advanced CT scanners, enhancing image quality and dose efficiency for healthcare providers.